[Pathophysiology and Clinical Presentation of Amyloid-Related Imaging Abnormality Induced by Anti-Amyloid-β Antibody Lecanemab].

Abstract

Lecanemab, the first monoclonal antibody drug targeting amyloid beta (Aβ), was approved for slowing the progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) in the United States and Japan. On the other hand, Amyloid-related imaging abnormalities (ARIA) has been reported in clinical trials, and its management and countermeasures remain a clinical issue. Given the large number of patients who is indicated of and would benefit from this type of AD therapy, physicians prescribing lecanemab should be familiar with how to appropriately manage and reduce the risks of ARIA. In this review, we outline the imaging characteristics and pathogenesis of ARIA that have emerged from the clinical trials and will also discuss risk factors and management protocol. (Recieved April 12, 2024; Accepted September 18, 2024; Published February 1, 2025).